Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Preferred Stock Liabilities: 2013

  • Larimar Therapeutics' Preferred Stock Liabilities was N/A to $103.8 million in Q4 2013 from the same period last year, while for Dec 2013 it was $103.8 million, marking a year-over-year change of. This contributed to the annual value of $103.8 million for FY2013, which is 65.32% up from last year.
  • According to the latest figures from Q4 2013, Larimar Therapeutics' Preferred Stock Liabilities is $103.8 million.
  • Over the past 5 years, Larimar Therapeutics' Preferred Stock Liabilities peaked at $103.8 million during Q4 2013, and registered a low of $103.8 million during Q4 2013.
  • Over the past 1 years, Larimar Therapeutics' median Preferred Stock Liabilities value was $103.8 million (recorded in 2013), while the average stood at $103.8 million.